Topic Hub
14 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 14 of 14 clinical reviews.
What parents and teens need to know before considering NMN or NR supplementation: current evidence, safety gaps, cognitive and athletic performance claims, and when to talk to a physician.
Read clinical reviewA clinician-reviewed guide to NMN and NR use in adolescents ages 12 to 17, covering NAD+ biology, evidence gaps, safety considerations, and how to manage the shift to adult care protocols at age 18.
Read clinical reviewA clinician-reviewed guide to NMN and NR supplementation in adults aged 65 and older, covering NAD+ biology, trial data, dosing, safety, and what geriatric patients should realistically expect.
Read clinical reviewA clinician-reviewed guide for caregivers managing NMN or NR supplementation in adults aged 65 and older, covering dosing, timing, drug interactions, monitoring, and when to pause.
Read clinical reviewA clinician-reviewed guide to NMN and NR supplementation in adults 65 and older, covering dosing, exercise timing, cognitive engagement, safety, and what current trial data actually shows.
Read clinical reviewA clinician-reviewed guide to NMN and NR supplementation for adults 65 and older, covering dosing, safety, drug interactions, monitoring, and how to transition geriatric patients to evidence-based NAD+ precursor protocols.
Read clinical reviewA clinician-reviewed guide to off-label NMN and NR use in adults 65 and older, covering NAD+ biology, trial data, dosing, safety, and what geriatric patients should discuss with their prescribers.
Read clinical reviewEvidence-based guidance for caregivers considering NMN or NR (nicotinamide mononucleotide/riboside) for children under age 12, including safety data, dosing considerations, and when to consult a physician.
Read clinical reviewA detailed clinical review of NMN and NR supplementation in adolescents aged 12 to 17, covering NAD+ biology, puberty, brain development, safety data, and why no regulatory body currently recommends these supplements for this age group.
Read clinical reviewA clinical review of off-label NMN and NR (nicotinamide mononucleotide and nicotinamide riboside) use in adolescents ages 12 to 17, covering the evidence base, safety signals, regulatory status, and what physicians should discuss with families.
Read clinical reviewA clinician-reviewed guide covering NMN/NR (nicotinamide mononucleotide/riboside) use in pediatric patients under 12, the evidence gaps, safety considerations, and how to structure the transition to adult NAD+ care protocols.
Read clinical reviewA physician-reviewed analysis of NMN and NR (nicotinamide mononucleotide and nicotinamide riboside) use in children under age 12, covering NAD+ biology, developmental safety data, regulatory status, and clinical guidance.
Read clinical reviewA clinician-reviewed guide to the evidence, risks, and regulatory status of NMN and NR supplementation in pediatric patients under age 12, including NAD+ biology, safety data, and clinical guidance.
Read clinical reviewAre NMN or NR supplements safe or appropriate for children under 12 attending school and participating in sports? A HealthRX clinical review of the evidence, risks, and current medical guidance.
Read clinical review